Afinitor meets breast cancer endpoint

Novartis AG (NYSE:NVS; SIX:NOVN) said oral Afinitor everolimus plus exemestane met the primary endpoint of progression-free survival (PFS) vs. placebo plus exemestane in the Phase III BOLERO-2 trial to treat breast cancer. The pharma subsequently stopped the trial early on the recommendation of an independent DMC. The double-blind trial enrolled more than 700 postmenopausal women with estrogen receptor-positive/HER2-negative, locally advanced or metastatic breast cancer refractory to letrozole or anastrozole. Novartis plans to submit regulatory applications worldwide for Afinitor in the indication by year end. ...